Photo: Diego M. Radzinschi/ALM

AbbVie Inc.'s blockbuster drug Humira costs the US health system $90,000 per patient each year. Now, an emerging competitor plans to sell an alternative at an 85% discount.

Coherus BioSciences Inc. will launch the cheapest-ever Humira copycat, Yusimry, in July, with a list price of $995 for two autoinjectors, the company said Thursday. That's far below the $6,922 AbbVie charges for the same supply of its drug used to treat rheumatoid arthritis, plaque psoriasis and other autoimmune conditions.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee-Paid
Employer-Paid